Asimov
@asimovbio.bsky.social
Asimov programs living cells to advance the design and manufacture of next-generation therapeutics. www.asimov.com
Read the report: https://itif.org/publications/2024/11/15/harnessing-ai-to-accelerate-innovation-in-the-biopharmaceutical-industry/
November 26, 2024 at 3:10 PM
Learn more: https://www.asimov.com/lv-edge-system
Asimov | LV Edge System
Integrating stable cell lines and software design tools to routinely achieve lentiviral titers over 1E8 TU/mL for therapeutic transgenes
www.asimov.com
November 25, 2024 at 1:14 PM
Learn more: https://www.asimov.com/lv-edge-system
8/ Cell therapies are complex and expensive to make. For these therapies to reach more patients, we must find ways to slash costs and make them at larger scales. Our platform, called LV Edge, combines wet-lab and computational tools to make lentivirus manufacturing and payload design much easier.
November 25, 2024 at 1:14 PM
8/ Cell therapies are complex and expensive to make. For these therapies to reach more patients, we must find ways to slash costs and make them at larger scales. Our platform, called LV Edge, combines wet-lab and computational tools to make lentivirus manufacturing and payload design much easier.
7/ In a clinical trial with 65 patients, 42% achieved complete remission within three months of receiving Aucatzyl, with a median remission duration of 14.1 months. Severe cases of cytokine release syndrome — a potentially dangerous side effect of CAR-Ts — were reported in just 3% of patients.
November 25, 2024 at 1:14 PM
7/ In a clinical trial with 65 patients, 42% achieved complete remission within three months of receiving Aucatzyl, with a median remission duration of 14.1 months. Severe cases of cytokine release syndrome — a potentially dangerous side effect of CAR-Ts — were reported in just 3% of patients.
6/ This rapid release allows the T cell to move on and attack multiple cancer cells in succession — a phenomenon known as "serial killing” — which enhances its tumor-killing efficiency.
November 25, 2024 at 1:14 PM
6/ This rapid release allows the T cell to move on and attack multiple cancer cells in succession — a phenomenon known as "serial killing” — which enhances its tumor-killing efficiency.
5/ The CAR protein that Aucatzyl it carries was designed to have a high dissociation rate. In other words, when a T cell engineered to express this “special” CAR grabs onto a cancer cell, it kills that cell and then disengages more rapidly than other immunotherapies.
November 25, 2024 at 1:14 PM
5/ The CAR protein that Aucatzyl it carries was designed to have a high dissociation rate. In other words, when a T cell engineered to express this “special” CAR grabs onto a cancer cell, it kills that cell and then disengages more rapidly than other immunotherapies.
4/ In the case of B-ALL, the T cell receptor that gets expressed binds CD19 — a protein commonly found on the surface of B cells, including cancerous ones. There are existing CAR-T therapies targeting this protein — including Tecartus — but Aucatzyl’s approach is distinct.
November 25, 2024 at 1:14 PM
4/ In the case of B-ALL, the T cell receptor that gets expressed binds CD19 — a protein commonly found on the surface of B cells, including cancerous ones. There are existing CAR-T therapies targeting this protein — including Tecartus — but Aucatzyl’s approach is distinct.
3/ Researchers take T cells from a patient, engineer them to express receptors specific to cancer cell surface proteins (often using lentivirus), and then reinfuse those cells into the patient’s bloodstream. Inside the body, the engineered T cells grab onto cancer cells and destroy them.
November 25, 2024 at 1:14 PM
3/ Researchers take T cells from a patient, engineer them to express receptors specific to cancer cell surface proteins (often using lentivirus), and then reinfuse those cells into the patient’s bloodstream. Inside the body, the engineered T cells grab onto cancer cells and destroy them.
2/ But first: CAR-T therapy stands for chimeric antigen receptor T cell therapy. It’s a form of immunotherapy that modifies a patient's own T cells (a type of white blood cell) to detect and attack cancer cells.
November 25, 2024 at 1:14 PM
2/ But first: CAR-T therapy stands for chimeric antigen receptor T cell therapy. It’s a form of immunotherapy that modifies a patient's own T cells (a type of white blood cell) to detect and attack cancer cells.
Learn more: www.asimov.com/aav-edge-sys...
AAV Edge System | Asimov
A comprehensive suite of tools for AAV payload design and production
www.asimov.com
November 22, 2024 at 8:52 PM
Learn more: www.asimov.com/aav-edge-sys...
8/ We are still validating this tool across more conditions, but all of our data so far suggests that these results are transferable across different cell lines and different cell types (HEK293, HEK293T, T-cells).
This codon optimizer is part of our AAV Edge platform.
This codon optimizer is part of our AAV Edge platform.
November 22, 2024 at 8:52 PM
8/ We are still validating this tool across more conditions, but all of our data so far suggests that these results are transferable across different cell lines and different cell types (HEK293, HEK293T, T-cells).
This codon optimizer is part of our AAV Edge platform.
This codon optimizer is part of our AAV Edge platform.
7/ Then, we packaged these payloads into AAVs and then transduced HEK293T cells with them. Finally, we studied protein expression levels using both microscopy and flow cytometry. The data are shown below (cells “glowing green” is a good thing, as is shifting purple peaks to the right.)
November 22, 2024 at 8:52 PM
7/ Then, we packaged these payloads into AAVs and then transduced HEK293T cells with them. Finally, we studied protein expression levels using both microscopy and flow cytometry. The data are shown below (cells “glowing green” is a good thing, as is shifting purple peaks to the right.)
6/ To test out our codon optimizer, we did an experiment: First, we took two clinically-relevant payloads — Luxturna and Zolgensma — and tagged of them with a fluorescent reporter protein. These sequences were either altered using our codon optimizer, or left intact.
November 22, 2024 at 8:52 PM
6/ To test out our codon optimizer, we did an experiment: First, we took two clinically-relevant payloads — Luxturna and Zolgensma — and tagged of them with a fluorescent reporter protein. These sequences were either altered using our codon optimizer, or left intact.
5/ Our codon optimizer does all this and more. It accounts for the entire lifecycle of a gene. When designing an AAV vector, for example, it considers not only “unpopular” codons, but also ensures the gene will be faithfully packaged into the vector, its mRNA won't degrade, and so on.
November 22, 2024 at 8:52 PM
5/ Our codon optimizer does all this and more. It accounts for the entire lifecycle of a gene. When designing an AAV vector, for example, it considers not only “unpopular” codons, but also ensures the gene will be faithfully packaged into the vector, its mRNA won't degrade, and so on.
4/ Modern codon optimizers do a lot more than just swap out “unpopular” codons. Some algorithms also check mRNA folding patterns to make sure the gene, once transcribed, won’t fold into weird structures that impede translation.
November 22, 2024 at 8:52 PM
4/ Modern codon optimizers do a lot more than just swap out “unpopular” codons. Some algorithms also check mRNA folding patterns to make sure the gene, once transcribed, won’t fold into weird structures that impede translation.
3/ If scientists want to take a gene from a plant + put it in a human cell, they’d use codon optimization to adjust the plant gene’s codons to match the human cell’s preferences, thus enhancing protein translation and boosting expression.
November 22, 2024 at 8:52 PM
3/ If scientists want to take a gene from a plant + put it in a human cell, they’d use codon optimization to adjust the plant gene’s codons to match the human cell’s preferences, thus enhancing protein translation and boosting expression.
2/ Consider, for example, the amino acid leucine. This amino acid can be encoded by several different codons (including CTT, CTC, and TTA), so codon optimization tools begin by swapping out unpopular codons and replacing them with more widely-used variants.
November 22, 2024 at 8:52 PM
2/ Consider, for example, the amino acid leucine. This amino acid can be encoded by several different codons (including CTT, CTC, and TTA), so codon optimization tools begin by swapping out unpopular codons and replacing them with more widely-used variants.
1/ A codon optimizer is a software tool that alters the sequence of a gene by adjusting its codons — the 3-nucleotide units encoding amino acids — to match the preferred codon usage in a specific organism.
November 22, 2024 at 8:52 PM
1/ A codon optimizer is a software tool that alters the sequence of a gene by adjusting its codons — the 3-nucleotide units encoding amino acids — to match the preferred codon usage in a specific organism.
8/ We are still validating this tool across more conditions, but all of our data so far suggests that these results are transferable across different cell lines and different cell types (HEK293, HEK293T, T-cells).
This codon optimizer is part of our AAV Edge platform.
This codon optimizer is part of our AAV Edge platform.
November 22, 2024 at 8:50 PM
8/ We are still validating this tool across more conditions, but all of our data so far suggests that these results are transferable across different cell lines and different cell types (HEK293, HEK293T, T-cells).
This codon optimizer is part of our AAV Edge platform.
This codon optimizer is part of our AAV Edge platform.
7/ Then, we packaged these payloads into AAVs and then transduced HEK293T cells with them. Finally, we studied protein expression levels using both microscopy and flow cytometry. The data are shown below (cells “glowing green” is a good thing, as is shifting purple peaks to the right.)
November 22, 2024 at 8:50 PM
7/ Then, we packaged these payloads into AAVs and then transduced HEK293T cells with them. Finally, we studied protein expression levels using both microscopy and flow cytometry. The data are shown below (cells “glowing green” is a good thing, as is shifting purple peaks to the right.)
6/ To test out our codon optimizer, we did an experiment: First, we took two clinically-relevant payloads — Luxturna and Zolgensma — and tagged of them with a fluorescent reporter protein. These sequences were either altered using our codon optimizer, or left intact.
November 22, 2024 at 8:50 PM
6/ To test out our codon optimizer, we did an experiment: First, we took two clinically-relevant payloads — Luxturna and Zolgensma — and tagged of them with a fluorescent reporter protein. These sequences were either altered using our codon optimizer, or left intact.
5/ Our codon optimizer does all this and more. It accounts for the entire lifecycle of a gene. When designing an AAV vector, for example, it considers not only “unpopular” codons, but also ensures the gene will be faithfully packaged into the vector, its mRNA won't degrade, and so on.
November 22, 2024 at 8:50 PM
5/ Our codon optimizer does all this and more. It accounts for the entire lifecycle of a gene. When designing an AAV vector, for example, it considers not only “unpopular” codons, but also ensures the gene will be faithfully packaged into the vector, its mRNA won't degrade, and so on.